Ceftriaxone
ALS
Massachusetts General HospitalSmall moleculePhase 3Dormant
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 81/ 100
Competitive context
17 Active assets in the ALS cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
mt-1186 Tanabe Pharma Corporation | Phase 3 | BB |
Ciprofloxacin NeuroSense Therapeutics Ltd. | Phase 2 | B |
Thalidomide Charite University, Berlin, Germany | Phase 2 | B |
Tocilizumab Barrow Neurological Institute | Phase 2 | B |
Talampanel Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 | B |
View all 27 →
Same molecule, other indications
Ceftriaxone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →